Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathwa…
$1.17+5.41%
报价 2026-11-06
市值
$25.6M
EV
$-40.1M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -92.6%
$1.08$15.82
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AARDAardvark Therapeutics, Inc. Common Stock | $25.6M | +5.4% | – | 0% | – | – | – | |
| EPRXEupraxia Pharmaceuticals Inc. | $455.2M | +4.4% | – | 0% | – | – | – | |
| ASMBAssembly Biosciences, Inc. | $415.8M | +2.1% | +57.1% | 72.9% | 54.5x | – | – | |
| ZURAZura Bio Limited | $394M | +9.9% | – | 0% | – | – | – | |
| AVTXAvalo Therapeutics, Inc. | $371.7M | +4.5% | 0.0% | -17,996.6% | – | – | – | |
| ENTAEnanta Pharmaceuticals, Inc. | $320.4M | +9.1% | -4.7% | 100% | – | – | – | |
| NAUTNautilus Biotechnology, Inc. | $284M | +3.7% | -61.1% | -362.5% | – | – | – | |
| FHTXFoghorn Therapeutics Inc. | $111.1M | -1.8% | -18.9% | 42.7% | – | – | – | |
| PYXSPyxis Oncology, Inc. | $105.2M | +3.1% | -100.0% | 99.8% | – | – | – | |
| 同行中位数 | – | – | -11.8% | 21.4% | 54.5x | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。